Application of T-LAK cell-originated protein kinase (TOPK) serving as cisplatin resistance therapy target for cervical cancer
The invention belongs to the field of anti-cervical cancer drugs, and particularly relates to application of T-LAK cell-originated protein kinase (TOPK) serving as a cisplatin resistance therapy target for cervical cancer. In the prior art, a relationship between the TOPK and cervical cancer prolife...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
09.06.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention belongs to the field of anti-cervical cancer drugs, and particularly relates to application of T-LAK cell-originated protein kinase (TOPK) serving as a cisplatin resistance therapy target for cervical cancer. In the prior art, a relationship between the TOPK and cervical cancer proliferation and cisplatin resistance is not yet studied. In order to clarify the mechanism of cisplatin resistance of cervical cancer patients, and provide a better therapeutic drug for the cervical cancer patients, the invention conducts a series of researches on the influences of TOPK on cervical cancer proliferation and cisplatin resistance. Results show that the TOPK is highly expressed in tissue of the cervical cancer patients, the TOPK promotes proliferation of cervical cancer cells, and overexpression of the TOPK promotes cisplatin resistance of the cervical cancer cells. A further study shows that a TOPK specific inhibitor OTS514 significantly inhibits proliferation of the cervical cancercells in vivo and in vit |
---|---|
Bibliography: | Application Number: CN202010047732 |